A comparison of clinical outcomes from updated Zuma-5 (Axicabtagene Ciloleucel) and the international scholar-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL)
Authors
Palomba, M. L.Ghione, P.
Patel, A. R.
Deighton, K.
Jacobson, C.
Nahas, M.
Jung, A. S.
Hatswell, A. J.
Kanters, S.
Limbrick-Oldfield, E.
Wade, S. W.
Snider, J. T.
Neelapu, S. S.
Riberio, M. T.
Gribben, J.
Radford, John A
Bobillo, S.
Ghesquieres, H.
Affiliation
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2021
Metadata
Show full item recordCitation
Palomba ML, Ghione P, Patel AR, Deighton K, Jacobson C, Nahas M, et al. A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL). Blood. 2021 Nov;138. PubMed PMID: WOS:000736413906109.Journal
BloodDOI
10.1182/blood-2021-147608Additional Links
https://dx.doi.org/10.1182/blood-2021-147608Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147608